727 reports of this reaction
1.8% of all RANIBIZUMAB reports
#13 most reported adverse reaction
ENDOPHTHALMITIS is the #13 most commonly reported adverse reaction for RANIBIZUMAB, manufactured by Genentech, Inc.. There are 727 FDA adverse event reports linking RANIBIZUMAB to ENDOPHTHALMITIS. This represents approximately 1.8% of all 41,498 adverse event reports for this drug.
Patients taking RANIBIZUMAB who experience endophthalmitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ENDOPHTHALMITIS is a less commonly reported adverse event for RANIBIZUMAB, but still significant enough to appear in the safety profile.
In addition to endophthalmitis, the following adverse reactions have been reported for RANIBIZUMAB:
The following drugs have also been linked to endophthalmitis in FDA adverse event reports:
ENDOPHTHALMITIS has been reported as an adverse event in 727 FDA reports for RANIBIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ENDOPHTHALMITIS accounts for approximately 1.8% of all adverse event reports for RANIBIZUMAB, making it a notable side effect.
If you experience endophthalmitis while taking RANIBIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.